Goals of treatment include prolonging life and improving quality of life.
The 5-year relative survival rate for women with metastatic breast cancer is 31.9%.[1] The longest median survival outcomes have been observed in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptorâ€“positive metastatic breast cancer, and less favorable outcomes have been observed in patients with metastatic triple-negative breast cancer (TNBC).[2] Treatment options for metastatic breast cancer include: Hormone therapy (tamoxifen, aromatase inhibitors, selective estrogen receptor [ER] degraders).